NCT04416594已完成不适用
Impact of Acquired FXIII Deficiency on Morbidity and Mortality Among Hospitalized Patients
Patricia Duque González1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2019年9月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Cut-Point levels of FXIII
研究概览
简要总结
Observational prospective study aiming to assess acquired FXIII deficiency implications in morbidity and mortality
详细描述
All patients admitted to a large tertiary hospital with FXIII levels below 70% during their hospital stay are assessed. Data regarding patient background, blood transfusion, morbidity and mortality is registered.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •FXIII levels < 70%
排除标准
- 未提供
结局指标
主要结局
Cut-Point levels of FXIII
时间窗: 2 years
The investigators aim to find a laboratory parameter, a cut-point plasma level of FXIII, to identify an increased in morbidity and mortality in a mixed cohort of hospitalized patients
次要结局
未报告次要终点
研究者
Patricia Duque González
Principal Investigator
Hospital General Universitario Gregorio Marañon
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Acquired FXIII Deficiency: Real World Evidence on Laboratory Diagnosis and presentation of FXIII supplementatioD68.4Acquired coagulation factor deficiencyDRKS00030706CSL Behring GmbH200
已完成
3 期
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyFactor XIII DeficiencyNCT00945906CSL Behring61
已完成
3 期
A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII DeficiencyFactor XIII DeficiencyNCT00885742CSL Behring41
已完成
不适用
Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational StudyCongenital Bleeding DisorderCongenital FXIII DeficiencyNCT01862367Novo Nordisk A/S30
已完成
不适用
Clinical Trial of Factor XIII (FXIII) ConcentrateFactor XIII DeficiencyHemophiliaNCT00640289Children's Hospital of Orange County72